HFA Cardio Talk

With Jozine M. ter Maaten, University Medical Centre Groningen, Groningen - Netherlands, Bart A. Mulder, 2022-2024, University Medical Centre Groningen, Groningen - Netherlands & Giuseppe Boriani, Polyclinic Modena University Hospital, Modena -Italy. Atrial fibrillation and heart failure often co-exist and influence each other. Treatment of AF specifically in the setting of heart failure can be challenging. Recently, new data emerged regarding the potential role of AF ablation in heart failure patients. In this podcast we discuss these in a special episode with a strong representation also from the EHRA Young highlighting the importance of interdisciplinary decision making in these patients. Recommended readings from this episode: CASTLE HTx CASTLE AF CABANA results in heart failure patients This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

Cardiologist Cornelia Margineanu from Bucharest, Romania, and Professor Thomas Felix Luscher from London, UK, discuss the future of heart failure specialists. They cover topics such as the evolution of heart failure treatment, challenges faced by future specialists, mentorship, career development, and exciting opportunities in cardiology.

Experts Mateusz Sokolski and Amina Rakisheva discuss the possibility of reversing heart failure, exploring factors influencing ejection fraction improvement, recovery definitions, cardiomyopathy diagnostic criteria, reversible causes like Fabry disease, and regenerative medicine with stem cell therapies and genetic considerations.

With Alberto Esteban-Fernández. Severo Ochoa University Hospital, Madrid - Spain & John McMurray. BHF Glasgow Cardiovascular Research Centre, Glasgow - UK. We discuss the implementation of 2021 HF guidelines, the possibility of implementing foundational therapy in clinical practice, and difficulties and barriers. Also, we discuss future heart failure treatments in the coming years. Access the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. "This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor."

With Antonio Cannata, King's College London - UK and Folkert Asselbergs, Amsterdam University Medical Centre - Netherlands. In this episode of HFA CardioTalk Antonio Cannata interviews one of the pioneer in digital medicine and artificial intelligence in cardiovascular medicine, Prof Folkert Asselbergs. Several interesting insights were discussed on the present role of AI in Heart Failure and what the future holds. "This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor."

With Henrike Arfsten,Medical University of Vienna - Austria & Antoni Bayes-Genis, Heart Institute, University Hospital Germans Trias and Pujol de Badalona - Spain In this episode of HFA CardioTalk, Henrike Arfsten interviews Antoni Bayes-Genis on circulating biomarkers in heart failure. They focus in particular on natriuretic peptides and discuss the benefits of biomarkers assessment and their fundamental role in heart failure diagnosis and disease progression. NEW! If you want to know more on this topic, access some recommended readings from the speakers: - Bayes-Genis A, et al.; Eur J Heart Fail. 2023 Sep 15 - Mueller C, et al.; Eur J Heart Fail. 2019 Jun;21(6):715-731. - Bayes-Genis A, et al.; Eur J Heart Fail. 2021:23,1432–1436. - Huelsmann M, et al.; J Am Coll Cardiol. 2013 Oct 8;62(15):1365-72 - Tsutsui H, et al; Eur J Heart Fail. 2023 May;25(5):616-631.

With Chris Kapelios, Onassis Cardiac Surgery Center, Athens - Greece & Gianluigi Savarese, Karolinska University Hospital, Stockholm - Sweden. This HFA CardioTalk podcast episode addresses Clinical inertia and optimization of heart failure therapy. The data we have on use of HF medications come from registries and may not be generalizable to unselected, real-world populations. The proportion of HFrEF patients treated with optimal medical therapy differs considerably among registries (between 70% to >90% for a beta-blocker, 60% to >90% for RASi, 15-45% for ARNI, 30-60% for MRA). It is well documented that optimal HFrEF treatment leads to better quality of life, and reduction in mortality, HF hospitalizations and healthcare costs. Clinical inertia is the lack of treatment intensification in patients not on optimized therapy. Its manifestations may differ from country to country, but it is always present, irrespective of whether the approach to HF medication initiation is sequential or in parallel. Increase of awareness, collaboration of all healthcare professionals, and use of checklists and digital tools are among the measures we can apply to tackle clinical inertia.

With Antonio Cannata, King's College London, London - UK & Stuart Pocock, London School of Hygiene & Tropical Medicine, London - UK. In this episode of HFA CardioTalk, Antonio Cannata interviews Stuart Pocock on how to understand randomised clinical trials. From the use of observational data to the key points in critically interpreting the results. Don't forget: a p value is no substitute for a brain.

With Henrike Arfsten, University of Vienna, Vienna - Austria, Juan Pablo Kaski, University College London, London - United Kingdom, Mateusz Sokolski, Wroclaw Medical University, Wroclaw - Poland, Jozine ter Maaten, University Medical Center Groningen, Groningen - the Netherlands, Peter van der Meer, University Medical Center Groningen, Groningen - the Netherlands, Antonio Cannata, King's College London, London - United Kingdom & Theresa McDonagh, King's College Hospital, London, United Kingdom. This podcast discusses two new guidelines and the results of two hot line presentation all presented at the ESC congress 2023 in Amsterdam, the Netherlands. First, Prof. Kaski shares highlights from the new and first ESC cardiomyopathy guidelines. Second, Prof. van der Meer discusses the results from the STEP HFpEF study in which semaglutide showed beneficial effect on weight, 6MWT and a win ratio compared to placebo in patients with the obesity phenotype of HFpEF. Next, Dr. ter Maaten discusses the results of the first randomized trial investigating the effect of natriuresis guided diuretic therapy in acute heart failure, as already incorporated in the guidelines. Finally, Prof. McDonagh walks us through the update of the ESC heart failure guidelines. The podcast is concluded with a brief discussion of some HFA Young highlights at the congress.

With Wilfred Mullens, Hospital Oost-Limburg (ZOL) and Hasselt University - Belgium & Alberto Esteban-Fernández, Hospital Universitario Severo Ochoa y Alfonso X El Sabio University - Spain. This podcast addresses some of the main developments in congestion management in heart failure patients, especially those with cardiorenal syndrome. We discuss the ADVOR and CLOROTIC trials and their implications for clinical practice.